Evidence map›Paper›PMID 38570882›Full record

ArticleDiagnostic pathology2024

Clinicopathological analysis of 22 Müllerian adenosarcomas and the sequencing of DICER1 mutation.

Xiaohong Yao, Wei Wang, Ying He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xiaohong YaoDepartment of Pathology, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
Wei WangDepartment of Pathology, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
Ying HeDepartment of Pathology, West China Second University Hospital, Sichuan University, Chengdu, 610041, China. heying626@163.com.
West China Second University Hospital of Sichuan University · CNSichuan University · CN

Funding

Key research and development project of cadre health care in Sichuan Province Research on diagnostic strategy and clinicopathological study of endometrial cancer molecular typing ZH2023-1701Sichuan Province Science and Technology Support Program 2022NSFSC0708Sichuan Science and Technology Department Natural Science Foundation "HPV vaccine clinical evaluation system and diagnostic kit development" 2023NSFSC0539The Clinical Discipline Development Fund of West China Second Hospital of Sichuan University, "Clinical Application Research on the Latest Molecular Typing Pathological Diagnosis Strategy and Scheme of Endometrial Cancer KS336
6 · The paper itself

Abstract

backgroundMüllerian adenosarcoma, a rare malignancy, presents diagnostic and therapeutic challenges. In this study, we conducted an analysis of the clinicopathological characteristics of 22 adenosarcomas, with a particular focus on screening for DICER1 hot mutations.

methodsThe cohort consisted of patients with adenosarcoma who were registered at the West China Second Hospital between the years 2020 and June 2022. Sanger sequencing was employed to screen for somatic Hotspot mutations in the RNase IIIb domain of DICER1 in the 22 adenosarcomas.

resultsOnly one patient exhibited a DICER1 mutation that was not a DICER1 Hotspot mutation. Among the 22 patients, all underwent total hysterectomy with bilateral salpingo-oophorectomy, and 14 out of these 22 patients received adjuvant treatment.

conclusionIn summary, our study of 22 Müllerian adenosarcomas focused on the clinicopathological features and the presence of DICER1 Hotspot mutations. Although our findings did not reveal any DICER1 mutations in the studied samples, this negative result provides valuable information for the field by narrowing down the genetic landscape of adenosarcomas and highlighting the need for further research into alternative molecular pathways driving this malignancy.

Indexed as

AdenosarcomaChinaDEAD-box RNA HelicasesFemaleHumansMutationRibonuclease IIIDEAD-box RNA HelicasesDICER1 protein, humanRibonuclease IIIAdenosarcomaDICER1 mutationGenetic screeningHotspot mutations

Identifiers

PMID38570882
PMCPMC10988924
OpenAlexW4393872484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.